Moezidis David sold $1.1M of BHE

Moezidis David (President and CEO) sold 12,500 shares of BENCHMARK ELECTRONICS INC (BHE) at $87.57 ($1.09M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moezidis David
Published May 26, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BHE
Neutral
medium confidence
Mentioned
$BHE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BHENeutralLow
01

Why it matters

The disclosure may slightly affect short-term sentiment, but planned 10b5-1 selling generally has lower informational content than unscheduled sales.

02

Market read

A planned insider sale is unlikely to drive fundamentals, but it can create brief volatility or sentiment-driven positioning.

03

What to watch

Traders may over-weight the sale size; the filing does not reveal whether additional insider buys/sales occurred around the same period or whether other news is pending.

Relevance 6/10Timing: Same-day disclosure (filed 2026-05-26) may cause brief sentiment noise around the next trading session.

Background

The article is an SEC Form 4 insider transaction disclosure for Benchmark Electronics (BHE) by its President and CEO, Moezidis David.

Company-level read

Ticker impact

$BHENeutralMedium confidence
Context

Benchmark Electronics CEO sold 12,500 shares in an open-market transaction for about $1.09M under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction may fade unless accompanied by other fundamental news.

Evidence & confidence

Form 4 shows a planned sale (10b5-1) and does not include new operational or financial information, so directional inference is constrained.

Market effects

Minimal—this is company-specific insider activity without sector-wide catalyst.

None indicated; transaction is a US-listed issuer insider sale.

None indicated; no international deal/regulatory element mentioned.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than negative expectations.

Key entities

  • BENCHMARK ELECTRONICS INC

    Subject of the SEC Form 4 insider sale by its President and CEO.

  • Moezidis David

    President and CEO who sold 12,500 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BHEHighAI 8/10

What Benchmark Electronics (BHE) Said on Its Q3 Earnings Call

Benchmark Electronics (BHE) reported Q3 growth in four of five end markets, with Semi-Cap revenue up 30% YoY. The company expects continued growth in 2027. It raised its Q4 and full-year outlook, forecasting 19% YoY revenue growth at the midpoint. BHE is investing in capacity and managing supply-chain constraints.

$BHEHighAI 8/10

Benchmark Electronics (BHE) Q3 2026 Earnings Call Transcript

Benchmark Electronics (BHE) reported Q3 2026 revenue of $811M, up 19% YoY, with non-GAAP EPS of $0.84, up 35% YoY. The company raised its full-year revenue outlook to over $3B. Semi-Cap and AC&C sectors drove growth, while Medical and Industrial also showed improvement. BHE expects Q4 revenue between $815M and $855M, with non-GAAP EPS between $0.85 and $0.91.

$BHEMedAI 8/10

Benchmark Electronics Inc (BHE) (Q3 2026) Earnings Call Highlights: Record Revenue

Benchmark Electronics (BHE) reported Q3 2026 earnings with record revenue and raised guidance. Aerospace & Defense revenue declined 1% YoY, and supply chain challenges persist. Inventory rose 16% sequentially. CEO David Moezidis cited customer forecasts and program ramps for growth confidence. The company expects capacity to support growth through 2027 and targets earnings growth at 1.5-2x revenue growth. Medical sector remains strong, with growth extending into 2028.